Concert Pharmaceuticals Overview

  • Founded
  • 2006
Founded
  • Status
  • Public
  • Employees
  • 64
Employees
  • Stock Symbol
  • CNCE
Stock Symbol
  • Share Price
  • $3.95
  • (As of Friday Closing)

Concert Pharmaceuticals General Information

Description

Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the currently approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's agitation.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 65 Hayden Avenue
  • Suite 3000N
  • Lexington, MA 02421
  • United States
+1 (781) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Concert Pharmaceuticals Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.95 $3.45 $2.57 - $4.62 $144M 36.3M 81.9K -$2.66

Concert Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV (10,241) 18,264 276,470 109,376
Revenue 32,573 32,578 7,902 1,077
EBITDA (93,702) (78,572) (73,246) (76,466)
Net Income (95,110) (80,051) (74,766) (78,166)
Total Assets 129,411 165,316 159,263 137,471
Total Debt 14,790 15,065 15,996 16,264
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Concert Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Concert Pharmaceuticals‘s full profile, request access.

Request a free trial

Concert Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Concert Pharmaceuticals‘s full profile, request access.

Request a free trial

Concert Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop smal
Biotechnology
Lexington, MA
64 As of 2021
00000
000000000 00000

00000

magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
0000000000000
Cambridge, MA
000 As of 0000
00000
000000&0

000000 0

derit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupida
0000 000000000
Boston, MA
0000 As of 0000
00.000
000 0000-00-00
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Concert Pharmaceuticals Competitors (39)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Agios Formerly VC-backed Cambridge, MA 000 00000 000000&0
000000 00000000000 Formerly VC-backed Boston, MA 0000 00.000 000000&0
0000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
0000000 0000000000 Formerly VC-backed Boston, MA 0 00000 000000000 00000
000000 000 0 Venture Capital-Backed Rehovot, Israel 0 000.00 0000000000 0 000.00
You’re viewing 5 of 39 competitors. Get the full list »

Concert Pharmaceuticals Patents

Concert Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020219797-A1 Process for preparing enantiomerically enriched jak inhibitors Pending 06-Feb-2019 0000000000
CA-3129096-A1 Process for preparing enantiomerically enriched jak inhibitors Pending 06-Feb-2019 0000000000
CA-3124399-A1 Deuterated forms and derivatives of volinanserin Pending 21-Dec-2018 0000000000
AU-2019403391-A1 Deuterated forms and derivatives of volinanserin Pending 21-Dec-2018 0000000000
EP-3897507-A1 Deuterated forms and derivatives of volinanserin Pending 21-Dec-2018 C07B59/002
To view Concert Pharmaceuticals’s complete patent history, request access »

Concert Pharmaceuticals Executive Team (9)

Name Title Board Seat Contact Info
Roger Tung Ph.D Chief Executive Officer & Founder
Nancy Stuart Chief Operating Officer, Operations
Jeffrey Munsie JD Secretary, Administration & Chief Legal Officer, Legal
James Cassella Ph.D Executive
Justine Koenigsberg Senior Vice President, Corporate Communications and Investor Relations
You’re viewing 5 of 9 executive team members. Get the full list »

Concert Pharmaceuticals Board Members (14)

Name Representing Role Since
Christine van Heek Concert Pharmaceuticals Board Member 000 0000
Jesper Hoiland Self Board Member 000 0000
Peter Hutt JD Self Board Member 000 0000
Richard Aldrich Self Chairman & Founder 000 0000
Ronald Barrett Ph.D Self Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Concert Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Concert Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Concert Pharmaceuticals‘s full profile, request access.

Request a free trial